Johnson & Johnson Reports Q1 2023 Results

New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)20232022% ChangeReported Sales$24,746$23,4265.6%Net Earnings/(Loss)($68)$5,149(101.3)%EPS (basic/diluted) 5($0.03)$1.93(101.6)%Q1Non-GAAP* ($ in Millions, except EPS)20232022% ChangeOperational Sales1,29.0%Adjusted Operational Sales1,37.6%Adjusted Net Earnings1,4$7,068$7,129(0.9)%Adjusted EPS (diluted)1,4$2.68$2.670.4%  1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules  2 Excludes the impact of translational currency  3 Excludes the net impact of acquisitions and divestitures and translational currency  4 Excludes intangible amortization expense and special items  5 Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutiveNote: values may have been roundedREGIONAL SALES RESULTSQ1% Change($ in Millions)...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Financial Source Type: news